{
    "xml": "<topic id=\"PHP5886\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/darbepoetin-alfa\" basename=\"darbepoetin-alfa\" title=\"DARBEPOETIN ALFA\">\n<title>DARBEPOETIN ALFA</title>\n<body>\n<data name=\"vtmid\">385610007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_871130604\" title=\"Epoetins\">Epoetins</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34585\" title=\"EPOETINS\" namespace=\"/drug-classes/epoetins\">EPOETINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP41473\" outputclass=\"indicationsAndDose\" rev=\"1.51\" parent=\"/drugs/darbepoetin-alfa\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia associated with chronic renal failure in patients on dialysis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection or by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 450&#8239;nanograms/kg once weekly, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose to be given once weekly or once every 2 weeks, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia associated with chronic renal failure in patients not on dialysis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 450&#8239;nanograms/kg once weekly, alternatively initially 750&#8239;nanograms/kg every 2&#8239;weeks, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose can be given once weekly, every 2 weeks, or once a month, subcutaneous route preferred in patients not on haemodialysis, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia associated with chronic renal failure in patients not on dialysis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 450&#8239;nanograms/kg once weekly, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose given once weekly, subcutaneous route preferred in patients not on haemodialysis, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 6.75&#8239;micrograms/kg every 3&#8239;weeks, alternatively initially 2.25&#8239;micrograms/kg once weekly, if response inadequate after 9 weeks further treatment may not be effective; if adequate response obtained then reduce dose by 25&#8211;50%, reduce dose by approximately 25&#8211;50% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41455\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/darbepoetin-alfa\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Injection-site pain</ph>; <ph outputclass=\"sideEffect\">oedema</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41467\" outputclass=\"pregnancy\" parent=\"/drugs/darbepoetin-alfa\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No evidence of harm in <i>animal</i> studies&#8212; manufacturer advises caution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41506\" outputclass=\"breastFeeding\" parent=\"/drugs/darbepoetin-alfa\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41485\" outputclass=\"hepaticImpairment\" parent=\"/drugs/darbepoetin-alfa\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41444\" outputclass=\"nationalFunding\" rev=\"1.37\" parent=\"/drugs/darbepoetin-alfa\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA323</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014)</p>\r\n<p>Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.</p>\r\n<p>If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA323\">www.nice.org.uk/TA323</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5886-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/darbepoetin-alfa\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74737\" title=\"Solution for injection\" namespace=\"/drugs/darbepoetin-alfa/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78590\" namespace=\"/treatment-summaries/anaemias\" title=\"Anaemias\" count=\"1\" rel=\"backlink\">Anaemias</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34585\" namespace=\"/drug-classes/epoetins\" title=\"EPOETINS\" count=\"1\" rel=\"link\">EPOETINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74737\" namespace=\"/drugs/darbepoetin-alfa/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP5886",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/darbepoetin-alfa",
    "basename": "darbepoetin-alfa",
    "title": "DARBEPOETIN ALFA",
    "vtmid": "385610007",
    "drugClassification": [
        "Epoetins"
    ],
    "inheritsFromClass": [
        "EPOETINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia associated with chronic renal failure in patients on dialysis",
                        "html": "Symptomatic anaemia associated with chronic renal failure in patients on dialysis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection or intravenous injection"
                    ],
                    "textContent": "By subcutaneous injection or by intravenous injection",
                    "html": "By subcutaneous injection or by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 450 nanograms/kg once weekly, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose to be given once weekly or once every 2 weeks, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment.",
                        "html": "<p>Initially 450&#8239;nanograms/kg once weekly, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose to be given once weekly or once every 2 weeks, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia associated with chronic renal failure in patients not on dialysis",
                        "html": "Symptomatic anaemia associated with chronic renal failure in patients not on dialysis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 450 nanograms/kg once weekly, alternatively initially 750 nanograms/kg every 2 weeks, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose can be given once weekly, every 2 weeks, or once a month, subcutaneous route preferred in patients not on haemodialysis, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment.",
                        "html": "<p>Initially 450&#8239;nanograms/kg once weekly, alternatively initially 750&#8239;nanograms/kg every 2&#8239;weeks, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose can be given once weekly, every 2 weeks, or once a month, subcutaneous route preferred in patients not on haemodialysis, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia associated with chronic renal failure in patients not on dialysis",
                        "html": "Symptomatic anaemia associated with chronic renal failure in patients not on dialysis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection"
                    ],
                    "textContent": "By intravenous injection",
                    "html": "By intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 450 nanograms/kg once weekly, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose given once weekly, subcutaneous route preferred in patients not on haemodialysis, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment.",
                        "html": "<p>Initially 450&#8239;nanograms/kg once weekly, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose given once weekly, subcutaneous route preferred in patients not on haemodialysis, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy",
                        "html": "Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 6.75 micrograms/kg every 3 weeks, alternatively initially 2.25 micrograms/kg once weekly, if response inadequate after 9 weeks further treatment may not be effective; if adequate response obtained then reduce dose by 25&#8211;50%, reduce dose by approximately 25&#8211;50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy.",
                        "html": "<p>Initially 6.75&#8239;micrograms/kg every 3&#8239;weeks, alternatively initially 2.25&#8239;micrograms/kg once weekly, if response inadequate after 9 weeks further treatment may not be effective; if adequate response obtained then reduce dose by 25&#8211;50%, reduce dose by approximately 25&#8211;50% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy.</p>"
                    }
                ]
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Injection-site pain",
                        "html": "Injection-site pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No evidence of harm in animal studies&#8212; manufacturer advises caution.",
                "html": "<p>No evidence of harm in <i>animal</i> studies&#8212; manufacturer advises caution.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution.",
                "html": "<p>Manufacturer advises caution.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA323",
                        "label": "www.nice.org.uk/TA323"
                    }
                ],
                "fundingIdentifier": "NICE TA323",
                "textContent": "Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014) Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy. If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.\n\nwww.nice.org.uk/TA323",
                "html": "<p outputclass=\"title\">Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014)</p> <p>Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.</p> <p>If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA323\">www.nice.org.uk/TA323</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74737",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78590",
                "label": "Anaemias",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "drugClass": [
            {
                "id": "PHP34585",
                "label": "EPOETINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74737",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}